|
1
|
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
|
Health Qual Life Outcomes
|
2006
|
26.32
|
|
2
|
Mcl-1; the molecular regulation of protein function.
|
FEBS Lett
|
2010
|
2.71
|
|
3
|
Pinning down proline-directed phosphorylation signaling.
|
Trends Cell Biol
|
2002
|
2.17
|
|
4
|
Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.
|
Pediatrics
|
2006
|
2.13
|
|
5
|
Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability.
|
J Biol Chem
|
2000
|
1.68
|
|
6
|
Phosphorylation stabilizes Nanog by promoting its interaction with Pin1.
|
Proc Natl Acad Sci U S A
|
2010
|
1.57
|
|
7
|
Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.
|
Pediatrics
|
2008
|
1.44
|
|
8
|
Interpreting patient-reported outcome results: US FDA guidance and emerging methods.
|
Expert Rev Pharmacoecon Outcomes Res
|
2011
|
1.43
|
|
9
|
A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group.
|
N Engl J Med
|
1992
|
1.42
|
|
10
|
Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency.
|
Mitochondrion
|
2006
|
1.23
|
|
11
|
The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.
|
Mol Genet Metab
|
2012
|
1.22
|
|
12
|
Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.
|
J Pharmacol Exp Ther
|
2007
|
1.20
|
|
13
|
EPI-743 reverses the progression of the pediatric mitochondrial disease--genetically defined Leigh Syndrome.
|
Mol Genet Metab
|
2012
|
1.17
|
|
14
|
The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?
|
Environ Health Perspect
|
2010
|
1.16
|
|
15
|
Reversible protein phosphorylation regulates circadian rhythms.
|
Cold Spring Harb Symp Quant Biol
|
2007
|
1.15
|
|
16
|
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
|
Invest New Drugs
|
2013
|
1.07
|
|
17
|
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.
|
J Clin Pharmacol
|
2011
|
1.03
|
|
18
|
Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.
|
Sci Transl Med
|
2013
|
1.02
|
|
19
|
Spectrum of neurological and survival outcomes in pyruvate dehydrogenase complex (PDC) deficiency: lack of correlation with genotype.
|
Mol Genet Metab
|
2012
|
1.01
|
|
20
|
Long-term safety of dichloroacetate in congenital lactic acidosis.
|
Mol Genet Metab
|
2013
|
0.93
|
|
21
|
Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism.
|
J Clin Endocrinol Metab
|
2004
|
0.92
|
|
22
|
Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate.
|
Biochem Pharmacol
|
1982
|
0.91
|
|
23
|
Phosphoproteomics.
|
Wiley Interdiscip Rev Syst Biol Med
|
2010
|
0.89
|
|
24
|
A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate.
|
Mol Genet Metab
|
2008
|
0.89
|
|
25
|
Unified gas chromatographic-mass spectrometric method for quantitating tyrosine metabolites in urine and plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.89
|
|
26
|
Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children.
|
J Clin Pharmacol
|
2014
|
0.87
|
|
27
|
The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders.
|
J Inherit Metab Dis
|
2014
|
0.87
|
|
28
|
Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary mitochondrial diseases.
|
Mitochondrion
|
2012
|
0.86
|
|
29
|
Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency.
|
J Pediatr
|
2001
|
0.86
|
|
30
|
Liquid chromatography-tandem mass spectrometry method for the simultaneous determination of delta-ALA, tyrosine and creatinine in biological fluids.
|
Clin Chim Acta
|
2004
|
0.85
|
|
31
|
Determination of dichloroacetate and its metabolites in human plasma by gas chromatography-mass spectrometry.
|
J Chromatogr B Biomed Sci Appl
|
1997
|
0.81
|
|
32
|
Preparation and stability of intravenous solutions of sodium dichloroacetate (DCA).
|
J Parenter Sci Technol
|
1992
|
0.77
|